Conventional magnetic resonance imaging key features for distinguishing pathologically confirmed corticobasal degeneration from its mimics: a retrospective analysis of the J-VAC study

Keita Sakurai; Aya M Tokumaru; Mari Yoshida; Yuko Saito; Koichi Wakabayashi; Takashi Komori; Masato Hasegawa; Takeshi Ikeuchi; Yuichi Hayashi; Takayoshi Shimohata; Shigeo Murayama; Yasushi Iwasaki; Toshiki Uchihara; Motoko Sakai; Ichiro Yabe; Satoshi Tanikawa; Hiroshi Takigawa; Tadashi Adachi; Ritsuko Hanajima; Harutoshi Fujimura; Kentaro Hayashi; Keizo Sugaya; Kazuko Hasegawa; Terunori Sano; Masaki Takao; Osamu Yokota; Tomoko Miki; Michio Kobayashi; Nobutaka Arai; Takuya Ohkubo; Takanori Yokota; Keiko Mori; Masumi Ito; Chiho Ishida; Jiro Idezuka; Yasuko Toyoshima; Masato Kanazawa; Masashi Aoki; Takafumi Hasegawa; Hirohisa Watanabe; Atsushi Hashizume; Hisayoshi Niwa; Keizo Yasui; Keita Ito; Yukihiko Washimi; Akatsuki Kubota; Tatsushi Toda; Kenji Nakashima; Ikuko Aiba; J-VAC study group

doi:10.1007/s00234-024-03432-w

Conventional magnetic resonance imaging key features for distinguishing pathologically confirmed corticobasal degeneration from its mimics: a retrospective analysis of the J-VAC study

Neuroradiology. 2024 Nov;66(11):1917-1929. doi: 10.1007/s00234-024-03432-w. Epub 2024 Jul 22.

Authors

Keita Sakurai¹, Aya M Tokumaru², Mari Yoshida³, Yuko Saito^{4

5}, Koichi Wakabayashi⁶, Takashi Komori⁷, Masato Hasegawa⁸, Takeshi Ikeuchi⁹, Yuichi Hayashi¹⁰, Takayoshi Shimohata¹⁰, Shigeo Murayama^{4

11}, Yasushi Iwasaki³, Toshiki Uchihara^{12

13}, Motoko Sakai¹⁴, Ichiro Yabe¹⁵, Satoshi Tanikawa¹⁶, Hiroshi Takigawa¹⁷, Tadashi Adachi¹⁷, Ritsuko Hanajima¹⁷, Harutoshi Fujimura¹⁸, Kentaro Hayashi¹⁹, Keizo Sugaya¹⁹, Kazuko Hasegawa²⁰, Terunori Sano²¹, Masaki Takao²¹, Osamu Yokota^{22

23}, Tomoko Miki^{22

23}, Michio Kobayashi²⁴, Nobutaka Arai²⁵, Takuya Ohkubo²⁶, Takanori Yokota²⁶, Keiko Mori²⁷, Masumi Ito²⁷, Chiho Ishida²⁸, Jiro Idezuka²⁹, Yasuko Toyoshima^{30

31}, Masato Kanazawa³², Masashi Aoki³³, Takafumi Hasegawa³³, Hirohisa Watanabe³⁴, Atsushi Hashizume³⁵, Hisayoshi Niwa³⁶, Keizo Yasui³⁷, Keita Ito³⁸, Yukihiko Washimi³⁹, Akatsuki Kubota⁴⁰, Tatsushi Toda⁴⁰, Kenji Nakashima⁴¹, Ikuko Aiba⁴²; J-VAC study group

Affiliations

¹ Department of Radiology, National Center for Geriatrics and Gerontology, Obu, Aichi, 474-8511, Japan.
² Department of Diagnostic Radiology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, 35-2 Sakae-Cho, Itabashi-Ku, Tokyo, 173-0015, Japan. [email protected].
³ Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute, Aichi, 480-1195, Japan.
⁴ Department of Neuropathology (the Brain Bank for Aging Research), Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi, Tokyo, 173-0015, Japan.
⁵ Department of Pathology and Laboratory Medicine, National Center of Neurology and Psychiatry, National Center Hospital, Kodaira, Tokyo, 187-8551, Japan.
⁶ Department of Neuropathology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, 036-8562, Japan.
⁷ Department of Laboratory Medicine and Pathology (Neuropathology), Tokyo Metropolitan Neurological Hospital, Fuchu, Tokyo, 183-0042, Japan.
⁸ Department of Brain & Neurosciences, Tokyo Metropolitan Institute of Medical Science, Setagaya, Tokyo, 156-8506, Japan.
⁹ Department of Molecular Genetics, Brain Research Institute, Niigata University, Chuo, Niigata, 951-8585, Japan.
¹⁰ Department of Neurology, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan.
¹¹ Brain Bank for Neurodevelopmental, Neurological and Psychiatric Disorders, United Graduate School of Child Development, Osaka University, Suita, Osaka, 565-0871, Japan.
¹² Department of General Internal Medicine, Okinawa Chubu Hospital, Uruma, Okinawa, 904-2293, Japan.
¹³ Laboratory of Structural Neuropathology, Tokyo Metropolitan Institute of Medical Science, Setagaya, Tokyo, 156-8506, Japan.
¹⁴ Department of Neurology, NHO Suzuka National Hospital, Suzuka, Mie, 513-8501, Japan.
¹⁵ Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, 060-8638, Japan.
¹⁶ Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Hokkaido, 001-0021, Japan.
¹⁷ Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Tottori, 683-8504, Japan.
¹⁸ Department of Neurology, NHO Osaka Toneyama Medical Center, Toyonaka, Osaka, 560-8552, Japan.
¹⁹ Department of Neurology, Tokyo Metropolitan Neurological Hospital, Fuchu, Tokyo, 183-0042, Japan.
²⁰ Department of Neurology, NHO Sagamihara National Hospital, Sagamihara, Kanagawa, 252-0392, Japan.
²¹ Department of Laboratory Medicine, National Center of Neurology and Psychiatry, National Center Hospital, Kodaira, Tokyo, 187-8551, Japan.
²² Department of Psychiatry, Kinoko Espoir Hospital, Kasaoka, Okayama, 714-0071, Japan.
²³ Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Kita, Okayama, 700-8558, Japan.
²⁴ Department of Neurology, NHO Akita National Hospital, Yurihonjo, Akita, 018-1393, Japan.
²⁵ Laboratory of Neuropathology, Tokyo Metropolitan Institute of Medical Science, Setagaya, Tokyo, 156-8506, Japan.
²⁶ Department of Neurology and Neurological Sciences, Tokyo Medical and Dental University, Bunkyo, Tokyo, 113-8519, Japan.
²⁷ Department of Neurology, Oyamada Memorial Spa Hospital, Yokkaichi, Mie, 512-1111, Japan.
²⁸ Department of Neurology, NHO Iou National Hospital, Kanazawa, Ishikawa, 920-0192, Japan.
²⁹ Department of Neurology, Ojiya Sakura Hospital, Ojiya, Niigata, 947-0041, Japan.
³⁰ Department of Neurology, Brain Disease Center Agano Hospital, Agano, Niigata, 959-2221, Japan.
³¹ Department of Pathology, Brain Research Institute, Niigata University, Chuo, Niigata, 951-8585, Japan.
³² Department of Neurology, Clinical Neuroscience Branch, Brain Research Institute, Niigata University, Chuo, Niigata, 951-8585, Japan.
³³ Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, 980-8574, Japan.
³⁴ Department of Neurology, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan.
³⁵ Department of Clinical Research Education, Nagoya University Graduate School of Medicine, Nagoya, Aichi, 466-8550, Japan.
³⁶ Department of Neurology, Kariya Toyota General Hospital, Kariya, Aichi, 448-8505, Japan.
³⁷ Department of Neurology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Aichi, 466-8650, Japan.
³⁸ Department of Neurology, Hekinan Municipal Hospital, Hekinan, Aichi, 447-8502, Japan.
³⁹ Department of Neurology, National Center for Geriatrics and Gerontology, Obu, Aichi, 474-8511, Japan.
⁴⁰ Department of Neurology, Graduate School of Medicine, The University of Tokyo, Bunkyo, Tokyo, 113-8655, Japan.
⁴¹ Department of Neurology, NHO Matsue Medical Center, Matsue, Shimane, 690-8556, Japan.
⁴² Department of Neurology, NHO Higashinagoya National Hospital, Nagoya, Aichi, 465-8620, Japan.

Abstract

Purpose: Due to the indistinguishable clinical features of corticobasal syndrome (CBS), the antemortem differentiation between corticobasal degeneration (CBD) and its mimics remains challenging. However, the utility of conventional magnetic resonance imaging (MRI) for the diagnosis of CBD has not been sufficiently evaluated. This study aimed to investigate the diagnostic performance of conventional MRI findings in differentiating pathologically confirmed CBD from its mimics.

Methods: Semiquantitative visual rating scales were employed to assess the degree and distribution of atrophy and asymmetry on conventional T1-weighted and T2-weighted images. Additionally, subcortical white matter hyperintensity (SWMH) on fluid-attenuated inversion recovery images were visually evaluated.

Results: In addition to 19 patients with CBD, 16 with CBD mimics (progressive supranuclear palsy (PSP): 9, Alzheimer's disease (AD): 4, dementia with Lewy bodies (DLB): 1, frontotemporal lobar degeneration with TAR DNA-binding protein of 43 kDa(FTLD-TDP): 1, and globular glial tauopathy (GGT): 1) were investigated. Compared with the CBD group, the PSP-CBS subgroup showed severe midbrain atrophy without SWMH. The non-PSP-CBS subgroup, comprising patients with AD, DLB, FTLD-TDP, and GGT, showed severe temporal atrophy with widespread asymmetry, especially in the temporal lobes. In addition to over half of the patients with CBD, two with FTLD-TDP and GGT showed SWMH, respectively.

Conclusion: This study elucidates the distinct structural changes between the CBD and its mimics based on visual rating scales. The evaluation of atrophic distribution and SWMH may serve as imaging biomarkers of conventional MRI for detecting background pathologies.

Keywords: Asymmetry; Corticobasal degeneration; Corticobasal syndrome; Magnetic resonance imaging; Subcortical white matter hyperintensity.

MeSH terms

Aged
Aged, 80 and over
Alzheimer Disease / diagnostic imaging
Alzheimer Disease / pathology
Atrophy
Corticobasal Degeneration* / diagnostic imaging
Diagnosis, Differential
Female
Humans
Lewy Body Disease / diagnostic imaging
Lewy Body Disease / pathology
Magnetic Resonance Imaging* / methods
Male
Middle Aged
Retrospective Studies
Supranuclear Palsy, Progressive / diagnostic imaging
Supranuclear Palsy, Progressive / pathology

Abstract

MeSH terms

Grants and funding